Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.4452W HIGH $1.90
Volume
5.49 M
Value Traded
2.07 M
Short % Float
12.38%
-14.27%Week
-22.78%1 Month
-35.55%3 Month
-30.73%6 Month
-89.39%5 Year
-89.18%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
124.20 M
EPS (TTM)
-0.35
P/E Ratio
-
Ent. Value
80.62 M
Total Shares
277.70 M
Float Shares
256.83 M
Insiders
7.55%
Institutions
26.67%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
HUMA Catalyst Timeline
Dated clinical, regulatory and corporate events for Humacyte, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Humacyte, Inc.
496Total events
12Upcoming
140Tier-1 (high impact)
2020 to 2027Coverage
Upcoming catalysts 2
Event history 50
●Management ChangeCorporate
Paul Kuznik appointed to Humacyte Board of Directors and Commercial Committee
▲Label ExpansionSymvessApprovedFDA Decision
FDA authorizes Symvess shelf life extension from 18 to 36 months
extremity arterial injurysource ↗
▲Manufacturing MilestoneSymvessApprovedCMC / Inspection
FDA authorizes extension of Symvess expiration dating from 18 months to 36 months
extremity arterial injurysource ↗
▲PublicationSymvessApprovedPresentation
Publication of V007 Phase 3 one-year results in The Lancet Digital Health
hemodialysis accesssource ↗
▲Topline ReadoutSymvessApprovedClinical Data
V012 dialysis access Phase 3 study topline results
dialysis accesssource ↗
▲IND ClearanceCTEVIND
FDA accepted IND for CTEV in CABG
coronary artery bypass grafting (CABG)source ↗
◆Trial InitiationCTEVTrial
Phase 2a study of CTEV in CABG expected to start this quarter
coronary artery bypass grafting (CABG)source ↗
▲Oral PresentationSymvessApprovedPresentation
V012 Phase 3 results presented at SVS Vascular Annual Meeting
hemodialysis access in womensource ↗
▲Primary Endpoint MetSymvessApprovedClinical Data
V012 met primary superiority endpoint of catheter-free days
hemodialysis access in womensource ↗
▲Topline ReadoutSymvessApprovedClinical Data
Top-line interim results from V012 Phase 3 study reported
hemodialysis access in female patientssource ↗
●Oral PresentationSymvessApprovedPresentation
V012 results to be presented at SVS Vascular Annual Meeting
dialysis access in female patientssource ↗
▲Primary Endpoint MetSymvessApprovedClinical Data
V012 met primary superiority endpoint
hemodialysis access in female patientssource ↗
▼Equity OfferingCorporate
Pricing of underwritten public offering of 47,619,048 shares at $1.05 per share
▲Primary Endpoint MetSymvessApprovedClinical Data
ATEV met primary endpoint of catheter-free days in V012 interim analysis
dialysis access in female patientssource ↗
▲Enrollment CompleteSymvessApprovedTrial
V012 enrollment terminated early due to meeting primary endpoint
dialysis access in female patientssource ↗
▲Full ResultsSymvessApprovedClinical Data
Positive results from V012 Phase 3 dialysis access study in women
hemodialysis accesssource ↗
▲Oral PresentationSymvessApprovedPresentation
Presentation of V012 top-line interim results at SVS VAM
dialysis accesssource ↗
▲Oral PresentationSymvessApprovedPresentation
Presentation at VASA 2026 symposium on self-repair of ATEV after cannulation
dialysis accesssource ↗
▲Product LaunchSymvessApprovedPost-Market
Symvess under contract with VA Strategic Acquisition Center
extremity vascular traumasource ↗
▲Other Regulator MilestoneSymvessApprovedEx-US Regulatory
Israeli Ministry of Health accepted Marketing Authorization Application for Symvess for arterial injury repair
arterial injury repairsource ↗
●IND SubmissionCTEVIND
IND application submitted to FDA for CTEV in CABG
coronary artery bypass graftingsource ↗
▼Restructuring LayoffsCorporate
Workforce restructuring reducing headcount by approximately 45 employees
▲Runway Guidance UpdateCorporate
Reduced expected spending by $14.3 million for remainder of 2026
◆Oral PresentationSymvessApprovedPresentation
Virtual KOL event to discuss ATEV for AV access in hemodialysis
arteriovenous (AV) access for hemodialysissource ↗
▲Partnership / LicenseSymvessApprovedCorporate
Realigned ex-U.S. rights to Symvess under amendment to distribution agreement with Fresenius Medical Care
▲FDA Filing AcceptedSymvessApprovedRegulatory Filing
Israel Ministry of Health accepts MAA for Symvess for vascular trauma repair
arterial trauma repairsource ↗
●Other Regulator MilestoneSymvessApprovedEx-US Regulatory
Israel Ministry of Health sets 180-working-day review period for Symvess MAA
arterial trauma repairsource ↗
◆Interim AnalysisSymvessApprovedTrial
Interim top-line results expected this quarter
hemodialysissource ↗
◆Topline ReadoutSymvessApprovedClinical Data
Top-line interim result from V012 Phase 3 study in hemodialysis access
hemodialysis accesssource ↗
◆Timing GuidanceSymvessApprovedPresentation
Planned supplemental BLA filing in 2nd half of 2026
dialysis AV accesssource ↗
◆Quarterly UpdateCorporate
Humacyte to announce 2025 Q4 and year-end financial results and provide business update
▲Partnership / LicenseSymvessApprovedCorporate
Received minimum purchase commitment of $1.475M for Symvess clinical evaluation and outreach program in KSA
vascular traumasource ↗
●EU MAA SubmissionSymvessApprovedEx-US Regulatory
MAA submitted to Israel Ministry of Health for Symvess for arterial trauma repair
arterial trauma repairsource ↗
◆Oral PresentationPresentation
Barclays 28th Annual Global Healthcare Conference Fireside Chat
▲Partnership / LicenseSymvessApprovedCorporate
Minimum $1.475M purchase commitment for clinical evaluation and outreach program in Saudi Arabia
arterial trauma repairsource ↗
●EU MAA SubmissionSymvessApprovedEx-US Regulatory
Submitted Marketing Authorization Application with Israel Ministry of Health for Symvess
arterial trauma repairsource ↗
▲Oral PresentationSymvessApprovedPresentation
Long-Term Outcomes of the Acellular Tissue Engineered Vessel in Extremity Arterial Trauma Repair: Results from the V005 Trial presented at VESS Annual Winter Meeting 2026
extremity arterial traumasource ↗
▲Other Regulator MilestoneEx-US Regulatory
FY2026 DoD Appropriations Act includes dedicated funding for biologic vascular repair technologies
traumatic vascular injuriessource ↗
▲Full ResultsSymvessApprovedClinical Data
Three-year results from V005 Phase 2/3 study published
extremity arterial injurysource ↗
●Oral PresentationSymvessApprovedPresentation
Presentation of hospital charge data analysis
extremity arterial injurysource ↗
Past FDA Catalysts and PDUFA Decisions
How HUMA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | ATEV (acellular tissue engineered vessel, V012) | Phase 3 topline data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C53 / 100
Pipeline Score
$600M
Pipeline Value
$2M
Commercial Value
Undervalued
Valuation Signal
2
Drugs Scored
4.6x
rNPV / MCap
Top 13%
Micro Cap(rank 86 of 658)
Percentile Rank
Humacyte, Inc. carries a moderate pipeline score (53/100), with $4.9B risk-adjusted pipeline value, led by Symvess in End-stage Renal Disease (Phase 3), across $147B in total addressable markets.
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $2.1M x 1.0 = $2M
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Symvess | $2M | - | - |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Symvess Monoclonal antibodyNCT05908084 | End-stage Renal Disease | Phase 3 | ACTIVE NOT_RECRUITING | 141 | Jun 1, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every HUMA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ATEV PriorityFast TrackRMAT | women on dialysis | Phase 3 | 2026-06-15 | average days free of catheter: 220 days for ATEV, 129 days for AV fistula; infections per 100 patient years: 6 for ATEV, 23 for AV fistula; six month catheter free days: 88 days for ATEV, 32 days for AV fistula; functional patency: 250 days for ATEV, 152 days for AV fistulaRead More | Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual MeetingRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Jones Keith AnthonyDirector | Buy | 10,000 50,000 held | $0.56 | 09/14/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in HUMA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| GREAT POINT PARTNERS LLC | 0.6 % (20 %) | 2.93 M | 3.75 M |
HUMA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-12-18 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How HUMA ranks across every disease it competes in
Competitive Position is a premium feature
See how HUMA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialHUMA News
HUMAHumacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik
Humacyte, Inc. has appointed Scott Coward and Paul Kuznik to its Board of Directors, enhancing its leadership team as it prepares for the commercial launch of its ATEV in dialysis access. Coward and Kuznik bring extensive experience in commercialization and life sciences, which is expected to support Humacyte's growth and product expansion. The company is focused on its innovative regenerative medicine technologies.
Read more →HUMAHumacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Humacyte, Inc. will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 16, 2026. CEO Laura Niklason will participate in a fireside chat, and management will be available for one-on-one meetings. The company focuses on developing universally implantable human tissues and has received FDA approvals for its acellular tissue engineered vessel.
Read more →HUMAHumacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 Months
Humacyte, Inc. announced that the FDA has authorized an extension of the expiration dating for its product, Symvess, from 18 months to 36 months. This decision is backed by additional stability data confirming that Symvess meets quality specifications throughout the extended period. The longer shelf life is expected to improve inventory management in hospitals and facilitate access to this critical product for urgent vascular repairs.
Read more →HUMAHumacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions
Humacyte, Inc. has confirmed its plans to file a supplemental Biologics License Application (BLA) for its acellular tissue engineered vessel (ATEV) aimed at dialysis access by November 2026. This filing will be supported by positive results from three Phase 3 studies, particularly highlighting the benefits seen in female patients. The ATEV is expected to provide a reliable option for patients who struggle with traditional dialysis access methods.
Read more →HUMA▲ +26.3%on this newsshared move
Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results
Humacyte has published one-year results from its V007 Phase 3 trial of the acellular tissue engineered vessel (ATEV) for hemodialysis access in The Lancet Digital Health. The study shows that ATEV outperforms traditional arteriovenous fistulas, especially benefiting women and men with obesity and diabetes. This publication adds validation to Humacyte's findings and supports plans for further regulatory submissions.
Read more →HUMABoard-Certified Vascular and Endovascular Surgeon Performs First Commercial Symvess® Implantation; Cites Bioengineered Blood Vessel as “Revolutionary Advancement”
Dr. Jeromy Brink, a vascular surgeon trained at Mayo Clinic, has successfully performed the first commercial implantation of Symvess in Arizona. This bioengineered blood vessel is the first and only FDA-approved option available off-the-shelf, which significantly reduces the time surgeons spend on harvesting vessels. The innovation is seen as a major advancement in the field of vascular surgery.
Read more →HUMA▼ -6.3%on this news· ran to -23% by day 1
Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update
Humacyte reported positive financial results for Q2 2026, highlighting breakthrough outcomes from its Phase 3 study of V012 for dialysis access. The study demonstrated that ATEV significantly outperformed the traditional AV fistula. The company plans to submit a supplemental Biologic License Application to the FDA in the latter half of 2026.
Read more →HUMAHumacyte To Announce 2026 Second Quarter Financial Results and Provide Business Update on August 12, 2026
Humacyte, Inc. will release its financial results for Q2 2026 on August 12, 2026. The company is known for developing bioengineered human tissues and has received FDA approval for its acellular tissue engineered vessel (ATEV) for vascular trauma. Management will provide a corporate update during a webcast following the results announcement.
Read more →HUMA▲ +7.9%on this news
Humacyte Announces FDA Acceptance of IND for First-In-Human Clinical Study of CTEV for Coronary Artery Bypass Grafting
Humacyte has announced the FDA's acceptance of its IND application for a first-in-human clinical study of the coronary tissue engineered vessel (CTEV) in coronary artery bypass grafting (CABG). The Phase 2a study is set to begin this quarter, aiming to evaluate the safety and efficacy of CTEV as a vascular conduit. This development is significant as it may offer a new off-the-shelf option for patients undergoing CABG.
Read more →HUMAHumacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis Access
Humacyte has appointed Dr. Robert J. Kossmann and Dr. Prabir Roy-Chaudhury as advisors to aid in the commercialization of the acellular tissue engineered vessel (ATEV) for hemodialysis access. Their extensive experience in nephrology will support health economic strategies and medical education. This follows promising results from a Phase 3 study, with plans for a supplemental Biologics License Application to the FDA.
Read more →HUMAHumacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting
Humacyte's Phase 3 V012 study results show that its bioengineered blood vessel, ATEV, offers significant advantages over the standard AV fistula for women on dialysis. Patients with ATEV experienced an average of three additional months without a dialysis catheter and had fewer infections. The company plans to file a supplemental BLA with the FDA later this year.
Read more →HUMA▼ -19.4%on this newsshared move
Humacyte, Inc. Announces Pricing of Public Offering of Common Stock
Humacyte, Inc. has announced the pricing of a public offering of 47,619,048 shares at $1.05 each, aiming to raise $50 million. The proceeds will be used for the commercialization of its product Symvess, among other corporate purposes. The offering is expected to close around June 12, 2026, pending customary conditions.
Read more →HUMAHumacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients
Humacyte announced positive interim results from the V012 Phase 3 study of its acellular tissue engineered vessel (ATEV) for dialysis access in female patients. The ATEV met its primary endpoint, showing significantly more catheter-free days than the standard AV fistula. The company plans to file a supplemental Biologic License Application with the FDA in late 2026, targeting patients with end-stage kidney disease.
Read more →HUMAHumacyte, Inc. Announces Proposed Public Offering of Common Stock
Humacyte, Inc. has announced a proposed public offering of its common stock to raise capital. The company plans to use the proceeds to fund the commercialization of its FDA-approved product, Symvess, and to support the development of its product pipeline. The offering is subject to market conditions and includes an option for underwriters to purchase additional shares.
Read more →HUMA▲ +5.7%on this news· ran to +24% by day 3
Humacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After Cannulation for Dialysis Access
Humacyte, Inc. announced the successful presentation of research at the VASA 2026 meeting, highlighting the self-repairing properties of its acellular tissue engineered vessel (ATEV) used in dialysis access. Findings suggest that despite frequent cannulation, ATEVs maintain structural integrity and promote smooth muscle cell repopulation over an extended period. Humacyte is expecting to release top-line interim results from its Phase 3 V012 study later in June, which may support further applications for the ATEV in hemodialysis.
Read more →HUMA▲ +11.1%on this news· ran to +34% by day 3shared move
Humacyte Announces Symvess is Now Under Contract with the Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs
Humacyte, Inc. has announced that its product Symvess is now under contract with the Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs. This contract will make Symvess more accessible across 170 VA hospitals by streamlining the approval process for healthcare professionals. Symvess is a first-in-class bioengineered tissue product that has received FDA approval for extremity vascular trauma indications. The company anticipates that this contract will enhance the visibility and availability of Symvess within the VA system.
Read more →HUMA▲ +24.2%on this news
Humacyte Announces First Quarter 2026 Financial Results and Provides Business Update
Humacyte, Inc. reported a strong financial performance for Q1 2026, with sales of Symvess reaching $0.5 million, a notable increase from $0.1 million in Q1 2025. The company has secured a significant purchase commitment for a clinical program in Saudi Arabia and is preparing for the presentation of interim results from its Phase 3 trial in hemodialysis access. Despite the positive developments, Humacyte faced a net loss and has reduced its workforce by 25%.
Read more →HUMA▼ -9%on this newsshared move
Humacyte Appoints Dr. Todd E. Rasmussen as Chief Surgical Officer
Humacyte, Inc. has appointed Dr. Todd E. Rasmussen as Chief Surgical Officer, leveraging his extensive experience in vascular surgery to enhance its leadership team. His role will focus on providing scientific support and medical education to healthcare professionals as the company prepares for increased clinical adoption of its Symvess® product. Rasmussen joins from the Mayo Clinic, where he will continue his clinical duties while contributing to Humacyte's development of bioengineered human tissues. His appointment comes as Humacyte's innovative products advance toward regulatory approval and market entry.
Read more →HUMAHumacyte To Announce 2026 First Quarter Financial Results and Provide Business Update on May 13, 2026
Humacyte, Inc. will announce its financial results for Q1 2026 on May 13, 2026. The company is known for developing bioengineered human tissues and has received FDA approval for its acellular tissue engineered vessel, Symvess. A conference call will follow the announcement to provide further updates on corporate and financial matters.
Read more →HUMA▲ +15.1%on this news
Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026
Humacyte, Inc. will host a virtual KOL event on April 28, 2026, to discuss its Acellular Tissue Engineered Vessel (ATEV) for hemodialysis patients. The event will feature experts who will address the current treatment landscape for patients with End-Stage Renal Disease (ESRD). The ATEV aims to provide a viable alternative to traditional AV fistulas, with ongoing trials showing promising results.
Read more →About Humacyte, Inc.
Headquarters2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM, NC, 27713
BIOPHARMAWATCH ELITE PLUS
Trade the next HUMA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime